E-islet 01 allogeneic human regenerative islets
EndoCell Therapeutics, Inc.
Early-stage; watch this space.
EndoCell Therapeutics' allogeneic human E-islet product is a stem-cell-derived islet-replacement approach delivered through the hepatic portal vein. A Phase 1/2a trial in adults with long-standing T1D, impaired hypoglycemia awareness, and severe hypoglycemia is recruiting in China; early human stem-cell-derived islet experience has been published, but the registered E-islet 01 trial has no posted efficacy results yet.
The scorecard
Published early human experience with autologous/allogeneic stem-cell-derived islets exists, and the E-islet 01 trial includes insulin-independence-adjacent endpoints, but this specific registered product has no posted efficacy results yet.[2]
The active trial follows participants for up to 5 years, but durable graft function for E-islet 01 is not yet reported.[1]
The registered product is allogeneic cells infused into the portal vein, with no immunosuppression-free protection strategy established in the public record. Nor does the platform's autologous work clear that bar: the celebrated E-islet "cure" was a man with type 2 diabetes who was already on chronic immunosuppression for a prior kidney transplant. There is no human evidence of an E-islet graft surviving without anti-rejection drugs.[3]
Portal-vein infusion is less invasive than a major implant operation but still carries the procedural burden and non-retrievability issues of intrahepatic islet transplantation.[1]
The current trial targets a narrow high-risk group: adults 18-75 with T1D, impaired hypoglycemia awareness, and severe hypoglycemia at a single listed Shanghai site.[1]
Recruiting Phase 1/2a trial with 21 planned participants; important but still early human development.[1]
The full picture
What it is
E-islet 01 is EndoCell Therapeutics' allogeneic human islet-replacement product for people with established type 1 diabetes who have impaired awareness of hypoglycemia and severe hypoglycemia.1 The public registry describes it as Allogeneic Human E-islet (E-islet 01), infused into the hepatic portal vein.1 That places it in the same broad family as donor-islet and Vertex zimislecel approaches: replacing missing insulin-producing cells rather than asking an algorithm to dose insulin around them.
Clinical status
The registered study, NCT07126873, is a Phase 1/2a, open-label, sequential trial at Shanghai Changzheng Hospital.1 It plans 21 adults aged 18-75, with follow-up to 5 years.1 The primary outcomes include safety/tolerability and the proportion of participants free of severe hypoglycemia with HbA1c improvement at 1 year after infusion.1 A registry check on 14 July 2026 confirmed the trial is still recruiting, with primary completion expected December 2027 and study completion December 2029; no results have been posted.1
What is known so far
The strongest published signal near this program is a 2026 Lancet Diabetes & Endocrinology report of autologous and allogeneic stem-cell-derived islet therapy in three people with T1D and complete loss of endogenous beta-cell function before transplant.2 That supports the broader E-islet platform as clinically plausible, but it does not mean the registered E-islet 01 trial has proved efficacy. ClinicalTrials.gov lists the E-islet 01 study as recruiting and does not post trial results.1
The autologous case does not mean "no drugs"
The E-islet platform is best known for a 2024 Cell Discovery report — a man who stopped needing insulin 11 weeks after receiving islets grown from his own reprogrammed blood cells, and who has stayed off it for years. It is widely retold as a cure achieved without anti-rejection drugs. Two things are wrong with that retelling:3
- He had type 2 diabetes, not type 1 — a 59-year-old with a 25-year history of T2D. On this site, Type 2 evidence never scores a Type 1 record, and it does not score this one.
- He was already immunosuppressed. He had developed end-stage diabetic nephropathy and received a kidney transplant in 2017, which means chronic systemic anti-rejection drugs were already on board when the E-islets went in.
This is the same pattern as the CiPSC "cured with her own cells" case in Tianjin, and the lesson is the same. Autologous cells answer allo-rejection — there is nothing foreign to reject. They do not answer the autoimmunity that destroys beta cells in type 1 diabetes; a perfectly matched graft is exactly the target those memory T cells were trained on. Nobody has yet shown a stem-cell-derived islet graft of any kind — autologous or allogeneic — surviving in an untreated type 1 immune system, with the single exception of Sana's gene-edited UP421 patient.
Key caveats
The registry does not establish an immunosuppression-free protection strategy, and the product is infused into the portal vein rather than placed in a retrievable device.1 Until public results clarify immune regimen, C-peptide durability, insulin-use reduction, and safety, this belongs as an early pipeline cell-replacement record, not a proven cure.
References
-
EndoCell Therapeutics, Inc. A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes. ClinicalTrials.gov NCT07126873 (last updated 2025). https://clinicaltrials.gov/study/NCT07126873 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
-
Shi Y, Feng Y, Li T, et al. Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic beta-cell function pretransplant. Lancet Diabetes Endocrinol (2026). https://doi.org/10.1016/S2213-8587%2825%2900423-1 ↩
-
Wu J, Li T, Guo M, et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discovery (30 April 2024). "The patient was a 59-year-old man with a 25-year history of T2D who developed end-stage diabetic nephropathy and underwent kidney transplantation in June of 2017." https://doi.org/10.1038/s41421-024-00662-3 ↩
Coming soon
ETA · Recruiting Phase 1/2a; primary completion estimated December 2027, study completion December 2029; no approval timing yet
- →First registered E-islet 01 safety, C-peptide, glucose, and insulin-use readouts · Trial follow-up runs through 2029
Sources
- [1]A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes · registry · 2025-08-17
- [2]Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic beta-cell function pretransplant · peer-reviewed · 2026-02-26
- [3]Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue · peer-reviewed · 2024-04-30 — The famous E-islet case. A 59-year-old man with a 25-year history of TYPE 2 diabetes who "developed end-stage diabetic nephropathy and underwent kidney transplantation in June of 2017" — i.e. already on chronic systemic immunosuppression when the autologous E-islets were transplanted. Type 2 evidence does not score a Type 1 record; it is cited here only to correct what the case is routinely claimed to show.